AML
MCID: LKM061
MIFTS: 81

Leukemia, Acute Myeloid (AML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 58 39
Acute Myeloid Leukemia 39 12 77 54 76 38 30 6 44 15 17
Leukemia, Acute Myelogenous 58 76 13 41
Acute Myelogenous Leukemia 12 77 54 15
Acute Undifferentiated Leukemia 60 56 74
Acute Myeloblastic Leukemia 12 77 76
Leukemia, Acute Myeloid, Susceptibility to 58 6
Leukemia, Myelocytic, Acute 12 74
Acute Myelocytic Leukemia 77 76
Leukemia, Myeloid, Acute 45 41
Aml 58 76
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 60
Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 60
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 58
Acute Myeloid Leukemia with Cebpa Somatic Mutations 60
Acute Myeloid Leukemia with Multilineage Dysplasia 60
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 58
Aml with Myelodysplasia-Related Features 60
Pure Familial Acute Myeloid Leukemia 60
Leukemia, Acute Myeloid, Somatic 58
Aml with Cebpa Somatic Mutations 60
Inherited Acute Myeloid Leukemia 60
Acute Non-Lymphoblastic Leukemia 76
Acute Myeloid Leukemia, Somatic 58
Aml with Multilineage Dysplasia 60
Acute Non-Lymphocytic Leukemia 76
Aml - Acute Myeloid Leukemia 12
Leukemia, Acute Myeloblastic 13
Acute Biphenotypic Leukemia 74
Pure Familial Aml 60
Inherited Aml 60
Familial Aml 60

Characteristics:

Orphanet epidemiological data:

60

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation


HPO:

33
leukemia, acute myeloid:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:9119
OMIM 58 601626
KEGG 38 H00003
ICD9CM 36 205.0
MeSH 45 D015470
NCIt 51 C27753 C3171
SNOMED-CT 69 17788007 91861009
ICD10 via Orphanet 35 C92.0 C92.8 C95.0
UMLS via Orphanet 75 C0280141 C0856823 C1292773
SNOMED-CT via HPO 70 124975008 263681008 413443009

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 44 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to core binding factor acute myeloid leukemia and leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Folotyn and Ixempra have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : 54 Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : 76 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : 77 Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 732)
# Related Disease Score Top Affiliating Genes
1 core binding factor acute myeloid leukemia 34.2 CEBPA FLT3 JAK2 KIT KRAS NRAS
2 leukemia 34.1 CEBPA CSF3R ETV6 FLT3 JAK2 KIT
3 acute myeloblastic leukemia with maturation 34.0 FLT3 KIT NPM1
4 cytogenetically normal acute myeloid leukemia 33.9 CEBPA FLT3 NPM1
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.7 ETV6 FLT3 KIT RUNX1
6 acute erythroid leukemia 33.6 CEBPA GATA2 JAK2 PICALM
7 acute leukemia 33.5 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
8 acute myeloblastic leukemia without maturation 33.2 FLT3 NPM1
9 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.2 CEBPA FLT3 KIT RUNX1
10 myeloid leukemia 33.0 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
11 lymphoid leukemia 31.6 ETV6 FLT3 JAK2
12 myeloid sarcoma 31.6 FLT3 KIT NPM1
13 acute promyelocytic leukemia 31.5 CEBPA CSF3R FLT3 NPM1 NRAS RUNX1
14 myelodysplastic syndrome 31.5 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
15 acute t cell leukemia 31.3 LPP MLLT10 NUP214
16 chronic myelomonocytic leukemia 31.2 CSF3R DNMT3A ETV6 FLT3 JAK2 KIT
17 leukemia, acute lymphoblastic 31.1 ETV6 FLT3 PICALM RUNX1
18 precursor t-cell acute lymphoblastic leukemia 31.1 ETV6 FLT3 MLLT10 NUP214 PICALM
19 leukemia, chronic myeloid 31.1 CSF3R ETV6 FLT3 GATA2 JAK2 KIT
20 myeloma, multiple 31.0 JAK2 KIT KRAS NRAS
21 bone marrow cancer 30.9 CSF3R ETV6 FLT3 JAK2 KIT RUNX1
22 juvenile myelomonocytic leukemia 30.9 DNMT3A FLT3 JAK2 KRAS NRAS RUNX1
23 neutrophilia, hereditary 30.9 CSF3R FLT3 JAK2
24 aplastic anemia 30.9 CSF3R FLT3 GATA2 NRAS TERT
25 myelodysplastic myeloproliferative cancer 30.9 CSF3R JAK2 NRAS
26 atypical chronic myeloid leukemia 30.8 CSF3R JAK2 RUNX1
27 aleukemic leukemia cutis 30.8 FLT3 NPM1 RUNX1
28 8p11 myeloproliferative syndrome 30.8 FLT3 KIT RUNX1
29 subacute myeloid leukemia 30.7 FLT3 JAK2
30 familial acute myeloid leukemia with mutated cebpa 12.7
31 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.4
32 cebpa-associated familial acute myeloid leukemia 12.4
33 aml with myelodysplasia-related features 12.1
34 megakaryocytic leukemia 11.9
35 acute monoblastic leukemia 11.9
36 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 11.5
37 acute myeloid leukemia with minimal differentiation 11.5
38 myelodysplastic syndrome with excess blasts 11.5
39 platelet disorder, familial, with associated myeloid malignancy 11.4
40 acute non lymphoblastic leukemia 11.4
41 shwachman-diamond syndrome 2 11.3
42 myeloproliferative/lymphoproliferative neoplasms, familial 11.3
43 erythroleukemia, familial 11.3
44 acute myeloid leukemia with t(9;11)(p22;q23) 11.3
45 acute myeloid leukemia with t(6;9)(p23;q34) 11.3
46 acute myeloid leukemia with npm1 somatic mutations 11.3
47 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 11.3
48 acute myeloid leukemia with t(8;16)(p11;p13) translocation 11.3
49 ataxia-pancytopenia syndrome 11.3
50 anemia, sideroblastic, 1 11.3

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Human phenotypes related to Leukemia, Acute Myeloid:

33
# Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 33 HP:0004808

Symptoms via clinical synopsis from OMIM:

58
Hematology:
acute myelogenous leukemia (aml)

Clinical features from OMIM:

601626

UMLS symptoms related to Leukemia, Acute Myeloid:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CEBPA CSF3R DNMT3A ETV6 KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
2 hematopoietic system MP:0005397 10.34 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
3 growth/size/body region MP:0005378 10.32 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
4 homeostasis/metabolism MP:0005376 10.32 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
5 mortality/aging MP:0010768 10.32 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
6 embryo MP:0005380 10.31 DNMT3A ETV6 GATA2 JAK2 KIT KRAS
7 immune system MP:0005387 10.27 CEBPA CSF3R DNMT3A ETV6 FLT3 JAK2
8 endocrine/exocrine gland MP:0005379 10.26 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
9 cardiovascular system MP:0005385 10.16 CEBPA ETV6 GATA2 KIT KRAS NPM1
10 integument MP:0010771 10.13 CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11 liver/biliary system MP:0005370 10.06 CEBPA GATA2 JAK2 KIT KRAS NPM1
12 neoplasm MP:0002006 10.02 CEBPA ETV6 FLT3 JAK2 KIT KRAS
13 no phenotypic analysis MP:0003012 9.86 CEBPA ETV6 FLT3 KIT KRAS NRAS
14 normal MP:0002873 9.81 CEBPA ETV6 GATA2 JAK2 KIT KRAS
15 pigmentation MP:0001186 9.35 CHIC2 KIT KRAS NRAS PICALM
16 reproductive system MP:0005389 9.23 CEBPA DNMT3A GATA2 JAK2 KIT KRAS

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
2
Ixempra 19 50 IXABEPILONE Bristol-Myers Squibb October 2007
3
Leukine 19 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
4
Mylotarg 19 50 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
5
Arcapta 19 INDACATEROL MALEATE Novartis July 2011

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 726)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
3
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
5
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
6
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
7
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
12
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
13
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
14
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
15
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
16
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
18
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
19
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
20
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 62-31-7, 51-61-6 681
22
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6 774
23
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
24
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 171228-49-2 147912
25
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
26
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
28
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
29
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
30
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
31
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
32 Molgramostim Investigational Phase 4,Phase 3 99283-10-0
33
Aclarubicin Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57576-44-0 451415
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Interferon-alpha Phase 4,Phase 2,Phase 1,Not Applicable
48 interferons Phase 4,Phase 2,Phase 1,Not Applicable
49 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2681)
# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
7 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
8 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
9 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
10 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
11 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
12 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
13 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
14 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
15 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
16 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
17 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
18 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
20 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
21 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4 Lenalidomide
22 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
23 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Completed NCT02267993 Phase 4 recombinant human thrombopoietin
24 Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML Not yet recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
25 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
26 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
27 King's Invasive Aspergillosis Study II Active, not recruiting NCT02875743 Phase 4 Posaconazole
28 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
29 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
30 A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
31 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
32 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
33 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
34 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
35 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
36 the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
37 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
38 Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia Unknown status NCT00342316 Phase 3
39 Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Unknown status NCT02244658 Phase 3 rhTPO
40 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
41 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
42 Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) Unknown status NCT01145846 Phase 3 Cytarabine plus Daunorubicin [Arm II (AD regimen)]
43 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
44 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Unknown status NCT02474290 Phase 2, Phase 3 Sorafenib
45 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
46 Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
47 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
48 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
49 Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
50 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 30 CBFB CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLF1 MLLT10 NPM1 NSD1 NUP214 PICALM RUNX1 SH3GL1 TERT

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

42
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 8195)
# Title Authors Year
1
Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. ( 30954792 )
2019
2
Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values. ( 30900388 )
2019
3
CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway. ( 30862962 )
2019
4
Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. ( 30776582 )
2019
5
Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )
2019
6
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. ( 30898482 )
2019
7
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. ( 30613922 )
2019
8
Multifocal muscle candidiasis of the legs in a patient with acute myeloid leukemia: A case report. ( 30813175 )
2019
9
Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse. ( 30686650 )
2019
10
High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. ( 30022221 )
2019
11
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. ( 30718798 )
2019
12
Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). ( 30899494 )
2019
13
Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia. ( 31109340 )
2019
14
Cellular therapy for acute myeloid Leukemia - Current status and future prospects. ( 31109711 )
2019
15
Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. ( 31111215 )
2019
16
Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy. ( 31111760 )
2019
17
Heterogeneity in refractory acute myeloid leukemia. ( 31064876 )
2019
18
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. ( 30104717 )
2019
19
Granulocyte Colony-Stimulating Factors in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia. ( 31070689 )
2019
20
Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. ( 31048355 )
2019
21
Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia. ( 31073071 )
2019
22
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). ( 31023346 )
2019
23
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. ( 30979868 )
2019
24
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. ( 30707502 )
2019
25
Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation. ( 30771495 )
2019
26
Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. ( 30715157 )
2019
27
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. ( 31000771 )
2019
28
Perforating Papules in a Patient With Acute Myeloid Leukemia. ( 31090880 )
2019
29
A case of extramedullary hematopoiesis presenting as hemorrhagic panniculitis and evolving in acute myeloid leukemia. ( 31095750 )
2019
30
MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia. ( 31022985 )
2019
31
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. ( 31055076 )
2019
32
Natural Products and Acute Myeloid Leukemia: A Review Highlighting Mechanisms of Action. ( 31058874 )
2019
33
Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco. ( 30988560 )
2019
34
Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. ( 31003190 )
2019
35
Clonal haematopoiesis and risk of acute myeloid leukemia. ( 31004019 )
2019
36
An Atypical Chronic Ulcer Caused by Acute Myeloid Leukemia. ( 31008718 )
2019
37
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. ( 31018543 )
2019
38
Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction. ( 30948486 )
2019
39
Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells. ( 30948782 )
2019
40
Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. ( 30953707 )
2019
41
Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia. ( 30953928 )
2019
42
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. ( 31101526 )
2019
43
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. ( 30361416 )
2019
44
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. ( 30792203 )
2019
45
MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide. ( 30982490 )
2019
46
Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. ( 31089274 )
2019
47
Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. ( 31018948 )
2019
48
Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia. ( 31050834 )
2019
49
Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion. ( 31000516 )
2019
50
Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. ( 30922328 )
2019

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

76
# Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 JAK2 p.Lys607Asn VAR_032696 rs121912472
3 JAK2 p.Val617Phe VAR_032697 rs77375493
4 SETBP1 p.Gly870Ser VAR_063809 rs267607040
5 SETBP1 p.Ser854Ala VAR_069848
6 SETBP1 p.Gly870Arg VAR_069854
7 SETBP1 p.Ile871Ser VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6 (show top 50) (show all 853)
# Gene Variation Type Significance SNP ID Assembly Location
1 CEBPA NM_004364.4(CEBPA): c.1021A> G (p.Ile341Val) single nucleotide variant Uncertain significance rs372931505 GRCh37 Chromosome 19, 33792300: 33792300
2 CEBPA NM_004364.4(CEBPA): c.1021A> G (p.Ile341Val) single nucleotide variant Uncertain significance rs372931505 GRCh38 Chromosome 19, 33301394: 33301394
3 CEBPA NM_004364.4(CEBPA): c.1018G> A (p.Gly340Ser) single nucleotide variant Uncertain significance rs375833261 GRCh38 Chromosome 19, 33301397: 33301397
4 CEBPA NM_004364.4(CEBPA): c.1018G> A (p.Gly340Ser) single nucleotide variant Uncertain significance rs375833261 GRCh37 Chromosome 19, 33792303: 33792303
5 CEBPA NM_004364.4(CEBPA): c.724G> A (p.Gly242Ser) single nucleotide variant Uncertain significance rs530569305 GRCh38 Chromosome 19, 33301691: 33301691
6 CEBPA NM_004364.4(CEBPA): c.724G> A (p.Gly242Ser) single nucleotide variant Uncertain significance rs530569305 GRCh37 Chromosome 19, 33792597: 33792597
7 CEBPA NM_004364.4(CEBPA): c.667G> A (p.Gly223Ser) single nucleotide variant Uncertain significance rs535980233 GRCh38 Chromosome 19, 33301748: 33301748
8 CEBPA NM_004364.4(CEBPA): c.667G> A (p.Gly223Ser) single nucleotide variant Uncertain significance rs535980233 GRCh37 Chromosome 19, 33792654: 33792654
9 CEBPA NM_004364.4(CEBPA): c.576G> A (p.Pro192=) single nucleotide variant Likely benign rs878854703 GRCh37 Chromosome 19, 33792745: 33792745
10 FLT3 NM_004119.2(FLT3): c.1715A> G (p.Tyr572Cys) single nucleotide variant Likely pathogenic rs121913491 GRCh38 Chromosome 13, 28034204: 28034204
11 FLT3 NM_004119.2(FLT3): c.1715A> G (p.Tyr572Cys) single nucleotide variant Likely pathogenic rs121913491 GRCh37 Chromosome 13, 28608341: 28608341
12 FLT3 NM_004119.2(FLT3): c.2506_2508delATC (p.Ile836del) deletion Likely pathogenic rs121913490 GRCh38 Chromosome 13, 28018500: 28018502
13 HRAS; LRRC56 NM_005343.3(HRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Likely pathogenic rs121913233 GRCh38 Chromosome 11, 533874: 533874
14 HRAS; LRRC56 NM_005343.3(HRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874
15 FLT3 NM_004119.2(FLT3): c.2506_2508delATC (p.Ile836del) deletion Likely pathogenic rs121913490 GRCh37 Chromosome 13, 28592637: 28592639
16 FLT3 NM_004119.2(FLT3): c.1855G> T (p.Gly619Cys) single nucleotide variant Likely pathogenic rs1057519769 GRCh38 Chromosome 13, 28033974: 28033974
17 FLT3 NM_004119.2(FLT3): c.1855G> T (p.Gly619Cys) single nucleotide variant Likely pathogenic rs1057519769 GRCh37 Chromosome 13, 28608111: 28608111
18 FLT3 NM_004119.2(FLT3): c.1952A> G (p.Asp651Gly) single nucleotide variant Likely pathogenic rs1057519768 GRCh38 Chromosome 13, 28028279: 28028279
19 FLT3 NM_004119.2(FLT3): c.1952A> G (p.Asp651Gly) single nucleotide variant Likely pathogenic rs1057519768 GRCh37 Chromosome 13, 28602416: 28602416
20 FLT3 NM_004119.2(FLT3): c.2026A> G (p.Asn676Asp) single nucleotide variant Likely pathogenic rs1057519767 GRCh38 Chromosome 13, 28028205: 28028205
21 FLT3 NM_004119.2(FLT3): c.2026A> G (p.Asn676Asp) single nucleotide variant Likely pathogenic rs1057519767 GRCh37 Chromosome 13, 28602342: 28602342
22 FLT3 NM_004119.2(FLT3): c.2028C> A (p.Asn676Lys) single nucleotide variant Likely pathogenic rs1057519766 GRCh38 Chromosome 13, 28028203: 28028203
23 FLT3 NM_004119.2(FLT3): c.2028C> A (p.Asn676Lys) single nucleotide variant Likely pathogenic rs1057519766 GRCh37 Chromosome 13, 28602340: 28602340
24 FLT3 NM_004119.2(FLT3): c.2028C> G (p.Asn676Lys) single nucleotide variant Likely pathogenic rs1057519766 GRCh38 Chromosome 13, 28028203: 28028203
25 FLT3 NM_004119.2(FLT3): c.2028C> G (p.Asn676Lys) single nucleotide variant Likely pathogenic rs1057519766 GRCh37 Chromosome 13, 28602340: 28602340
26 FLT3 NM_004119.2(FLT3): c.2059A> T (p.Ile687Phe) single nucleotide variant Likely pathogenic rs1057519765 GRCh38 Chromosome 13, 28027236: 28027236
27 FLT3 NM_004119.2(FLT3): c.2059A> T (p.Ile687Phe) single nucleotide variant Likely pathogenic rs1057519765 GRCh37 Chromosome 13, 28601373: 28601373
28 FLT3 NM_004119.2(FLT3): c.2073T> A (p.Phe691Leu) single nucleotide variant Likely pathogenic rs1057519764 GRCh38 Chromosome 13, 28027222: 28027222
29 FLT3 NM_004119.2(FLT3): c.2073T> A (p.Phe691Leu) single nucleotide variant Likely pathogenic rs1057519764 GRCh37 Chromosome 13, 28601359: 28601359
30 FLT3 NM_004119.2(FLT3): c.2073T> G (p.Phe691Leu) single nucleotide variant Likely pathogenic rs1057519764 GRCh38 Chromosome 13, 28027222: 28027222
31 FLT3 NM_004119.2(FLT3): c.2073T> G (p.Phe691Leu) single nucleotide variant Likely pathogenic rs1057519764 GRCh37 Chromosome 13, 28601359: 28601359
32 FLT3 NM_004119.2(FLT3): c.2503_2504delGAinsTT (p.Asp835Phe) indel Likely pathogenic rs1057519763 GRCh38 Chromosome 13, 28018504: 28018505
33 FLT3 NM_004119.2(FLT3): c.2503_2504delGAinsTT (p.Asp835Phe) indel Likely pathogenic rs1057519763 GRCh37 Chromosome 13, 28592641: 28592642
34 FLT3 NM_004119.2(FLT3): c.2524T> C (p.Tyr842His) single nucleotide variant Likely pathogenic rs1057519762 GRCh38 Chromosome 13, 28018484: 28018484
35 FLT3 NM_004119.2(FLT3): c.2524T> C (p.Tyr842His) single nucleotide variant Likely pathogenic rs1057519762 GRCh37 Chromosome 13, 28592621: 28592621
36 FLT3 NM_004119.2(FLT3): c.2525A> G (p.Tyr842Cys) single nucleotide variant Likely pathogenic rs376588714 GRCh38 Chromosome 13, 28018483: 28018483
37 FLT3 NM_004119.2(FLT3): c.2525A> G (p.Tyr842Cys) single nucleotide variant Likely pathogenic rs376588714 GRCh37 Chromosome 13, 28592620: 28592620
38 SF3B1 NM_012433.3(SF3B1): c.2098A> C (p.Lys700Gln) single nucleotide variant Likely pathogenic rs559063155 GRCh38 Chromosome 2, 197402110: 197402110
39 SF3B1 NM_012433.3(SF3B1): c.2098A> C (p.Lys700Gln) single nucleotide variant Likely pathogenic rs559063155 GRCh37 Chromosome 2, 198266834: 198266834
40 SF3B1 NM_012433.3(SF3B1): c.2098A> T (p.Lys700Ter) single nucleotide variant Likely pathogenic rs559063155 GRCh38 Chromosome 2, 197402110: 197402110
41 SF3B1 NM_012433.3(SF3B1): c.2098A> T (p.Lys700Ter) single nucleotide variant Likely pathogenic rs559063155 GRCh37 Chromosome 2, 198266834: 198266834
42 SF3B1 NM_012433.3(SF3B1): c.2099A> C (p.Lys700Thr) single nucleotide variant Likely pathogenic rs1057519756 GRCh38 Chromosome 2, 197402109: 197402109
43 SF3B1 NM_012433.3(SF3B1): c.2099A> C (p.Lys700Thr) single nucleotide variant Likely pathogenic rs1057519756 GRCh37 Chromosome 2, 198266833: 198266833
44 SF3B1 NM_012433.3(SF3B1): c.2099A> G (p.Lys700Arg) single nucleotide variant Likely pathogenic rs1057519756 GRCh38 Chromosome 2, 197402109: 197402109
45 SF3B1 NM_012433.3(SF3B1): c.2099A> G (p.Lys700Arg) single nucleotide variant Likely pathogenic rs1057519756 GRCh37 Chromosome 2, 198266833: 198266833
46 SF3B1 NM_012433.3(SF3B1): c.2099A> T (p.Lys700Ile) single nucleotide variant Likely pathogenic rs1057519756 GRCh38 Chromosome 2, 197402109: 197402109
47 SF3B1 NM_012433.3(SF3B1): c.2099A> T (p.Lys700Ile) single nucleotide variant Likely pathogenic rs1057519756 GRCh37 Chromosome 2, 198266833: 198266833
48 SF3B1 NM_012433.3(SF3B1): c.2100A> C (p.Lys700Asn) single nucleotide variant Likely pathogenic rs1057519755 GRCh38 Chromosome 2, 197402108: 197402108
49 SF3B1 NM_012433.3(SF3B1): c.2100A> C (p.Lys700Asn) single nucleotide variant Likely pathogenic rs1057519755 GRCh37 Chromosome 2, 198266832: 198266832
50 SF3B1 NM_012433.3(SF3B1): c.2100A> T (p.Lys700Asn) single nucleotide variant Likely pathogenic rs1057519755 GRCh38 Chromosome 2, 197402108: 197402108

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 232758 8 119200000 127300000 Insertion MYC Acute myeloid leukemia
2 232759 8 119200000 127300000 Insertion NSE2 Acute myeloid leukemia
3 232760 8 119200000 127300000 Insertion TRIB1 Acute myeloid leukemia
4 232757 8 119200000 127300000 Insertion FLJ32440 Acute myeloid leukemia
5 232756 8 119200000 127300000 Insertion C8FW Acute myeloid leukemia
6 232517 8 117700000 119200000 Deletion Acute myeloid leukemia
7 231360 8 104000 47043000 Gain Acute myeloid leukemia
8 230513 7 99529552 99529633 Deletion Acute myeloid leukemia
9 230511 7 99529327 99529406 Deletion miR-93 Acute myeloid leukemia
10 230509 7 99529119 99529202 Deletion miR-25 Acute myeloid leukemia
11 229606 7 92302000 156450000 Loss Acute myeloid leukemia
12 229568 7 92068000 92292000 Gain Acute myeloid leukemia
13 229366 7 90633327 119508217 Deletion Acute myeloid leukemia
14 228440 7 76108000 158812000 Gain or loss Acute myeloid leukemia
15 208359 6 168087000 169485000 Gain Acute myeloid leukemia
16 208073 6 164500000 171115067 Copy number MLLT4 Acute myeloid leukemia
17 206240 6 137855022 140711307 Duplication Acute myeloid leukemia
18 206076 6 135555189 135763913 Gain MYB Acute myeloid leukemia
19 206075 6 135555189 135763913 Gain AHI1 Acute myeloid leukemia
20 204737 6 114621527 115238795 Loss Acute myeloid leukemia
21 204410 6 110000 42427000 Gain Acute myeloid leukemia
22 203935 6 104200000 106000000 Gain Acute myeloid leukemia
23 203875 6 1033000 27766000 Loss Acute myeloid leukemia
24 203701 6 1 60500000 Insertion TNF Acute myeloid leukemia
25 203700 6 1 60500000 Insertion PBX2 Acute myeloid leukemia
26 203321 5 97054000 101265000 Gain Acute myeloid leukemia
27 203276 5 96271209 168210016 Deletion Acute myeloid leukemia
28 175189 3 37985899 37985975 Deletion Acute myeloid leukemia
29 174928 3 35760972 35761055 Deletion Acute myeloid leukemia
30 174461 3 26371277 81284264 Deletion Acute myeloid leukemia
31 173099 3 189889263 189889348 Deletion miR-28 Acute myeloid leukemia
32 172501 3 182993000 199318000 Gain Acute myeloid leukemia
33 172485 3 182700000 187900000 Deletion Acute myeloid leukemia
34 172407 3 18124000 50667000 Loss Acute myeloid leukemia
35 172263 3 179722000 179941000 Loss Acute myeloid leukemia
36 171585 3 170129000 199318000 Gain Acute myeloid leukemia
37 171169 3 163995351 164109297 Gain Acute myeloid leukemia
38 170926 3 161605227 161605307 Deletion Acute myeloid leukemia
39 170923 3 161605070 161605167 Deletion miR-15b Acute myeloid leukemia
40 169892 3 148103000 199318000 Gain or loss Acute myeloid leukemia
41 168151 3 127549061 128880998 Deletion Acute myeloid leukemia
42 166190 3 1 95713000 Gain or loss Acute myeloid leukemia
43 166151 3 1 91700000 Deletion MLH1 Acute myeloid leukemia
44 166124 3 1 80807000 Gain or loss Acute myeloid leukemia
45 166109 3 1 54393000 Gain or loss Acute myeloid leukemia
46 165626 22 47354576 49468408 Amplification Acute myeloid leukemia
47 165625 22 47354576 49468408 Amplification Acute myeloid leukemia
48 165438 22 44927000 49560000 Gain Acute myeloid leukemia
49 165336 22 44003066 49202107 Deletion Acute myeloid leukemia
50 164829 22 39818559 39906027 Translate EP300 Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

38
# Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 CEBPA CSF3R FLT3 JAK2 KIT KRAS
2
Show member pathways
13.2 CSF3R FLT3 JAK2 KIT KRAS NRAS
3
Show member pathways
12.64 CSF3R FLT3 JAK2 KIT KRAS NRAS
4
Show member pathways
12.63 CEBPA FLT3 KIT KRAS NRAS RUNX1
5 12.35 CEBPA GATA2 JAK2 KIT RUNX1
6
Show member pathways
12.26 CSF3R JAK2 KRAS NRAS
7
Show member pathways
12.16 FLT3 JAK2 KRAS NRAS
8 12.05 CEBPA ETV6 FLT3 RUNX1
9 12 CEBPA CSF3R FLT3 JAK2 KIT KRAS
10 11.93 FLT3 JAK2 KIT NPM1
11
Show member pathways
11.81 JAK2 KRAS NRAS
12 11.77 JAK2 KRAS NRAS
13 11.75 CSF3R FLT3 KIT
14 11.61 CSF3R JAK2 KRAS NRAS
15 11.6 CEBPA KIT NRAS
16 11.5 GATA2 NPM1 TERT
17
Show member pathways
11.48 JAK2 KRAS NRAS
18
Show member pathways
11.38 FLT3 KIT KRAS NRAS
19 11.16 JAK2 KRAS NRAS
20 11.07 FLT3 KIT KRAS NRAS
21 10.84 DNMT3A ETV6 FLT3
22 10.67 KRAS NRAS

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2 nucleus GO:0005634 9.8 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3 focal adhesion GO:0005925 9.02 JAK2 KRAS LPP NPM1 NUP214

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 FLT3 JAK2 KIT KRAS NPM1
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 CEBPA DNMT3A ETV6 GATA2 NSD1 RUNX1
3 negative regulation of gene expression GO:0010629 9.78 GATA2 PICALM RUNX1 TERT
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.58 FLT3 JAK2 KIT
5 MAPK cascade GO:0000165 9.55 FLT3 JAK2 KIT KRAS NRAS
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 FLT3 JAK2 KIT
7 positive regulation of MAP kinase activity GO:0043406 9.5 FLT3 KIT KRAS
8 hematopoietic stem cell proliferation GO:0071425 9.49 ETV6 RUNX1
9 regulation of myeloid cell differentiation GO:0045637 9.46 CSF3R RUNX1
10 cytokine-mediated signaling pathway GO:0019221 9.43 CEBPA CSF3R FLT3 JAK2 KIT KRAS
11 myeloid progenitor cell differentiation GO:0002318 9.26 FLT3 KIT
12 hemopoiesis GO:0030097 9.02 RUNX1 PICALM FLT3 GATA2 KIT

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 DNMT3A GATA2 MLLT10 NPM1 NSD1
2 protein binding GO:0005515 9.6 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
3 nucleotide binding GO:0000166 9.55 FLT3 JAK2 KIT KRAS NRAS
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.43 CEBPA DNMT3A ETV6 GATA2 NSD1 RUNX1

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....